Research Topics
| Robert A BurgerSummaryAffiliation: University of California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group StudyRobert A Burger
University of California, Irvine Medical Center, Building 56, Room 264, 101 The City Dr, Orange, CA 92868, USA
J Clin Oncol 25:5165-71. 2007..We conducted a phase II trial to assess the efficacy and tolerability of single-agent bevacizumab, an anti-VEGF monoclonal antibody...- Experience with bevacizumab in the management of epithelial ovarian cancerRobert A Burger
University of California, Irvine Medical Center, Irvine, Orange, CA 92868, USA
J Clin Oncol 25:2902-8. 2007.... - Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancerErnest S Han
University of California Irvine, Orange, CA, USA
Gynecol Oncol 119:484-90. 2010..Potential predictive/prognostic angiogenic markers were prospectively examined in a phase II trial of bevacizumab in epithelial ovarian cancer (EOC)/primary peritoneal cancer (PPC)... - A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancerTroy A Gatcliffe
Department of Ob Gyn, Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
Gynecol Oncol 112:85-9. 2009..The objective of this study was to assess the feasibility of adding weekly topotecan to cisplatin in patients with primary, locally advanced carcinoma of the cervix receiving pelvic irradiation... - Prognostic relevance of carbonic anhydrase-IX in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group studyShu Yuan Liao
Department of Epidemiology, University of California at Irvine, School of Medicine, Irvine, CA, USA
Gynecol Oncol 116:452-8. 2010.... - Prospective evaluation of an in vitro radiation resistance assay in locally advanced cancer of the uterine cervix: a Southwest Oncology Group StudyLeslie M Randall
Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
Gynecol Oncol 119:417-21. 2010..To investigate the feasibility of performing a fresh-tissue, in vitro radiation resistance assay (IVRRA) in a cooperative group setting and to assess the association of IVRRA results with clinical outcomes... - Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group studyLeslie M Randall
Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
Gynecol Oncol 112:583-9. 2009..To determine whether markers of tumor angiogenesis were associated with progression-free survival (PFS) and overall survival (OS) in women with high-risk, early-stage cervical cancer treated on a phase III trial... - Conservation of in vitro drug resistance patterns in epithelial ovarian carcinomaKrishnansu S Tewari
The Division of Gynecologic Oncology, The Chao Family Comprehensive Cancer Center, University of California, Irvine-Medical Center, 101 The City Drive, Orange, CA 92868, USA
Gynecol Oncol 98:360-8. 2005..It is possible that assay results at diagnosis could be used to guide subsequent therapy at relapse, especially when recurrent tissue is not available for analysis... - Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group studyBradley J Monk
University of California, Irvine Medical Center, Bldg 56, Room 262, 101 The City Dr, Orange, CA 92868 USA
J Clin Oncol 27:1069-74. 2009..The Gynecologic Oncology Group (GOG) conducted a phase II trial to assess the efficacy and tolerability of bevacizumab, a recombinant humanized anti-vascular endothelial growth factor monoclonal antibody... - Gemcitabine and cisplatin chemotherapy is an active combination in the treatment of platinum-resistant ovarian and peritoneal carcinomaDevansu Tewari
Chao Family Comprehensive Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine-Medical Center, 101 The City Drive, Orange, CA 92868, USA
Invest New Drugs 22:475-80. 2004.... - Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancerBradley J Monk
Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, 1012 The City Drive, Orange, CA 92868, USA
Gynecol Oncol 102:140-4. 2006..We reviewed our experience with BEV in patients with recurrent advanced epithelial ovarian cancer who had failed multiple prior chemotherapeutic regimens... - Gene expression profiling of in vitro radiation resistance in cervical carcinoma: a feasibility studyDevansu Tewari
Division of Gynecologic Oncology, University of California Irvine Medical Center, 101 The City Drive South, Orange, CA 92868, USA
Gynecol Oncol 99:84-91. 2005..The potential of these technologies for cancers in which radiotherapy is employed warrants further investigation... - Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trialLeslie M Randall
Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, CA 92868, USA
Gynecol Oncol 124:563-8. 2012.... - Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group studyRobert A Burger
Department of Obstetrics and Gynecology, University of California-Irvine Medical Center, Orange, CA, USA
Cancer 101:106-15. 2004.... - Development of an in vitro chemo-radiation response assay for cervical carcinomaBradley J Monk
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, University of California, Irvine, Orange, California 92868, USA
Gynecol Oncol 87:193-9. 2002..The assay was feasible for examining fresh tumors and may be an important tool for studying RT or drug resistance. Clinical trials to evaluate this assay are indicated... - Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancerBradley J Monk
Division of Gynecologic Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine, Medical Center, 101 The City Drive, Building 56, Room 262, Orange CA 92868, USA
Gynecol Oncol 96:902-5. 2005..An objective durable response lasting at least 5 months was documented. CONCLUSION: Bevacizumab has activity in epithelial ovarian carcinoma and larger scale trials are indicated... - In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancerNoelle Gillette Cloven
University of California Irvine, Orange, CA 92868, USA
Gynecol Oncol 92:160-6. 2004..The data collected in this investigation may provide a guide for stratification of patients entering clinical trials based on histology and biomarker expression... - Primary invasive vaginal cancer in the setting of the Mayer-Rokitansky-Kuster-Hauser syndromeDevansu S Tewari
Division of Gynecologic Oncology, Division of Radiation Oncology, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, 101 The City Drive, Orange, CA 92868, USA
Gynecol Oncol 85:384-7. 2002..It is a reminder that routine gynecologic examinations are still warranted as these patients are at risk for malignant changes in residual mullerian tissues... - Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapyAnnie Yessaian
Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California, Irvine-Medical Center, Orange, CA 92868, USA
Gynecol Oncol 94:61-6. 2004..According to recently published randomized clinical trials, most patients should receive adjuvant postoperative therapy. The benefits of this multimodality approach require randomized study... - Treatment of recurrent gynecologic malignancies with iodine-125 permanent interstitial irradiationBradley J Monk
Division of Gynecologic Oncology, The Chao Family N.C.I.-Designated Comprehensive Cancer Center, University of California, Irvine-Medical Center, Orange, CA 92868, USA
Int J Radiat Oncol Biol Phys 52:806-15. 2002..In radiotherapy-naive patients with unresectable isolated recurrent gynecologic malignancies, 125I implants and EBRT are feasible and occasionally may contribute to long-term disease-free survival... - Prognostic factors in neuroendocrine small cell cervical carcinoma: a multivariate analysisJohn K Chan
Division of Gynecologic Oncology, The Chao Family Comprehensive Cancer Center, University of California-Irvine Medical Center, Orange, California 92868, USA
Cancer 97:568-74. 2003..The role of primary or postoperative radiation with or without chemotherapy is unclear and yields uniformly poor results, particularly in patients with advanced lesions. Clinical trials are needed... - Early stage cervical cancers containing human papillomavirus type 18 DNA have more nodal metastasis and deeper stromal invasionSamuel S Im
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Chao Family Comprehensive Cancer Center, University of California-Irvine Medical Center, 101 The City Drive, Orange, CA 92868, USA
Clin Cancer Res 9:4145-50. 2003..Despite an increased use of adjuvant radiation therapy, these cancers are still more likely to relapse... - Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat modelJohn K Chan
Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford Cancer Center, 300 Pasteur Drive HH333, Stanford, CA 94305 5317, USA
Cancer Res 65:3243-8. 2005..Thus, EGFR blockade may ultimately prove to be a useful therapeutic tool in the treatment of cisplatin-sensitive and cisplatin-resistant ovarian cancers... - Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancerStephen A Cannistra
Beth Israel Deaconess Medical Center, East Campus KS158, 330 Brookline Ave, Boston, MA 02215, USA
J Clin Oncol 25:5180-6. 2007.... - Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group StudyJoan L Walker
Department of Obstetrics and Gynecology, University of Oklahoma, PO Box 26901, Oklahoma City, OK 73190, USA
Gynecol Oncol 100:27-32. 2006..To evaluate reasons for discontinuing intraperitoneal (IP) chemotherapy, and to compare characteristics of patients who did versus did not successfully complete six cycles of IP chemotherapy... - Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a gynecologic oncology group studyJeffrey M Fowler
Division of Gynecologic Oncology, Ohio State University, Columbus, OH 43210, USA
Gynecol Oncol 85:311-4. 2002..8%. The duration of the partial response was 15.2 months. CONCLUSION: Oral TMTX has insignificant activity in the treatment of advanced, persistent, and recurrent uterine MMT at the dose and schedule administered... - Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group studyRobert F Ozols
Medical Science Department, Fox Chase Cancer Center, Philadelphia, PA, USA
J Clin Oncol 21:3194-200. 2003..CONCLUSION: In patients with advanced ovarian cancer, a chemotherapy regimen consisting of carboplatin plus paclitaxel results in less toxicity, is easier to administer, and is not inferior, when compared with cisplatin plus paclitaxel... - Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group StudyHolly H Gallion
Division of Gynecologic Oncology, Magee Women s Hospital University of Pittsburgh, Pittsburgh, PA, USA
J Clin Oncol 21:3808-13. 2003..To determine if circadian timed (CT) chemotherapy results in improved response, progression-free survival (PFS), overall survival (OS), and lower toxicity, when compared with standard timed (ST) chemotherapy. Materials and.. - Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group StudyGini F Fleming
Gynecologic Oncology Group, Four Penn Center, 1600 JFK Blvd, Suite 1020, Philadelphia, PA 19103, USA
J Clin Oncol 22:2159-66. 2004..Secondary comparisons included progression-free survival (PFS), response rate (RR), and toxicities... - A new model of ovarian carcinogenesis may influence early detection strategiesRobert A Burger
Am J Obstet Gynecol 198:349-50. 2008 - Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group studyJ Tate Thigpen
Division of Oncology, Department of Medicine, University of Mississippi School of Medicine, Jackson, USA
J Clin Oncol 22:3902-8. 2004..These results have served as a building block for subsequent phase III trials in patients with disseminated and high-risk limited endometrial carcinoma... - Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group StudyDavid R Spriggs
Division of Solid Tumor Oncology, Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:4466-71. 2007..This study was undertaken to assess if prolonged paclitaxel administration in combination with cisplatin improves overall survival (OS) in epithelial ovarian cancer (EOC)... - Phase II trial of pulse dactinomycin as salvage therapy for failed low-risk gestational trophoblastic neoplasia: a Gynecologic Oncology Group studyAllan Covens
Division of Gynecology Oncology, University of Toronto, Toronto, Ontario, Canada
Cancer 107:1280-6. 2006..The purpose of the study was to determine the activity and toxicity of pulse dactinomycin as salvage treatment of patients with low-risk gestational trophoblastic neoplasia (GTN) who failed methotrexate therapy... - Intraperitoneal cisplatin and paclitaxel in ovarian cancerDeborah K Armstrong
Johns Hopkins Kimmel Cancer Center, Baltimore, USA
N Engl J Med 354:34-43. 2006..CONCLUSIONS: As compared with intravenous paclitaxel plus cisplatin, intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel improves survival in patients with optimally debulked stage III ovarian cancer... - Implications of second-look laparotomy in the context of optimally resected stage III ovarian cancer: a non-randomized comparison using an explanatory analysis: a Gynecologic Oncology Group studyBenjamin E Greer
Division of Gynecologic Oncology, University of Washington, Fred Hutchinson Cancer Research Center, Puget Sound Oncology Consortium LF 287, 1100 Fairview Avenue N, Seattle, WA 98109, USA
Gynecol Oncol 99:71-9. 2005....
Research Grants
- Angiogenesis Targeted Therapeutics of Ovarian CancerRobert Burger; Fiscal Year: 2006..Finally, Dr. Burger will generate a logical sequence of original publications and extramural funding specific to the proposed work. ..